Consensus estimates for Avenue Therapeutics Inc (ATXI) stock’s next quarter

As of close of business last night, Avenue Therapeutics Inc’s stock clocked out at $0.15, down -4.30% from its previous closing price of $0.15. In other words, the price has decreased by -$0.0066 from its previous closing price. On the day, 746697 shares were traded. Ratios: To gain a deeper understanding of ATXI’s stock, we […]

Avenue Therapeutics Inc (ATXI) Stock Price Fluctuations: Highs and Lows

In the latest session, Avenue Therapeutics Inc (NASDAQ: ATXI) closed at $0.15 down -4.49% from its previous closing price of $0.16. In other words, the price has decreased by -$0.0071 from its previous closing price. On the day, 1582541 shares were traded. Ratios: For a deeper understanding of Avenue Therapeutics Inc’s stock, let’s take a […]

Avenue Therapeutics Inc (ATXI)’s financial ratios: A comprehensive overview

Avenue Therapeutics Inc (NASDAQ: ATXI) closed the day trading at $0.16 up 1.61% from the previous closing price of $0.16. In other words, the price has increased by $+0.0012 from its previous closing price. On the day, 2458775 shares were traded. Ratios: For a better understanding of ATXI, let’s look at its different ratios. For […]

Analysts predict high and low EPS estimates for Avenue Therapeutics Inc (ATXI)

In the latest session, Avenue Therapeutics Inc (NASDAQ: ATXI) closed at $0.16 down -15.63% from its previous closing price of $0.19. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 4001034 shares were traded. ATXI stock price reached its highest trading level at $0.1785 during the session, […]

Examining Avenue Therapeutics Inc (ATXI)’s cash flow and debt position

In the latest session, Avenue Therapeutics Inc (NASDAQ: ATXI) closed at $0.17 down -0.65% from its previous closing price of $0.17. In other words, the price has decreased by -$0.0011 from its previous closing price. On the day, 2287552 shares were traded. Ratios: For a deeper understanding of Avenue Therapeutics Inc’s stock, let’s take a […]